#PharmaIntelligence #GenericDrugs #RegulatoryAffairs #PharmacodiaGlobal #ChinaPharma #DrugDevelopment To view or add a comment, sign in Canada Adopts ICH M13A Guideline for Some Modified Release (MR) Products Based on: Health Canada's official notice on ICH M13A implementation Link to Notice What is ICH M13A
Any rapid weight loss, including weight loss from a GLP-1 medication, can include some loss of muscle as well as fat
Smoothies, broth-based soups, and easy-to-digest protein sources are your best allies
Behavioral and mental health support Some GLP-1 users experience emotional challenges after discontinuing treatment or during rapid body change
As longevity medicine increasingly focuses on preserving physiological function rather than merely extending lifespan, immune optimization has become a major therapeutic target
However, you may also experience serious side effects, and you will likely have to keep taking the drug forever because youre not addressing any of the underlying causes behind your weight gain or weight loss resistance
